Inhibition of the proteasome reduces transfer-induced diabetes in nonobese diabetic mice

Scandinavian Journal of Immunology

Volumn 60, Issue 1, 2004, Pages 134-142

  Petrovic, J ^a   Hall, H ^a   Mehr, R ^b   Glas, R ^a,c   Hoglund P ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b BAR ILAN UNIVERSITY   (Israel)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; CALPAIN; PROTEASOME INHIBITOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL INFILTRATION; CELL MIGRATION; CELL PROLIFERATION; CELL TRANSFER; CONTROLLED STUDY; DOSE RESPONSE; INSULIN DEPENDENT DIABETES MELLITUS; LYMPH NODE; MOUSE; NONHUMAN; OBESITY; PANCREAS; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; T LYMPHOCYTE;

ADOPTIVE TRANSFER; ANIMALS; CELL DIVISION; CYSTEINE ENDOPEPTIDASES; CYSTEINE PROTEINASE INHIBITORS; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 1; FLOW CYTOMETRY; GLYCOSURIA; ISLETS OF LANGERHANS; LEUPEPTINS; LYMPH NODES; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED NOD; MICE, TRANSGENIC; MULTIENZYME COMPLEXES; PROTEASOME ENDOPEPTIDASE COMPLEX; T-LYMPHOCYTES;

EID: 3242692570     PISSN: 03009475     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.0300-9475.2004.01473.x     Document Type: Article

References (34)

1. Castano L, Eisenbarth GS. Type-I diabetes: a chronic autoimmune disease of human, mouse, and rat. Annu Rev Immunol 1990;8:647-79.
2. Adorini L, Gregori S, Harrison LC. Understanding autoimmune diabetes: insights from mouse models. Trends Mol Med 2002;8:31-8.
3. Höglund P, Mintern J, Waltzinger C, Heath W, Benoist C, Mathis D. Initiation of autoimmune diabetes by developmentally regulated presentation of islet cell antigens in the pancreatic lymph nodes. J Exp Med 1999;189:331-9.
4. Andre I, Gonzalez A, Wang B, Katz J, Benoist C, Mathis D. Checkpoints in the progression of autoimmune disease: lessons from diabetes models. Proc Natl Acad Sci USA 1996;93:2260-3.
5. Atkinson MA, Leiter EH. The NOD mouse model of type 1 diabetes: as good as it gets? Nat Med 1999;6:601-4.
6. Gagnerault MC, Luan JJ, Lotton C, Lepault F. Pancreatic lymph nodes are recuired for priming of beta cell reactive T cell in NOD mice. J Exp Med 2002;196:369-77.
7. Ciechanover A. The ubiqiotin-proteasome pathway, on protein death and cell life. EMBO J 1998;24:7151-60.
8. Baumeister W, Walz J, Zuhl F, Seemuller E. The proteasome: paradigm of a self-compartmentalizing protease. Cell 1998;92:367-80.
9. Forloni G, Terreni L, Bertani I et al. Protein misfolding in Alzheimer's and Parkinson's disease: genetics and molecular mechanisms. Neurobiol Aging 2002;23:957-76.
10. Adams J. Proteasome inhibition in cancer: development of PS-341. Semin Oncol 2001;28:613-9.
11. Teicher BA, Ara G, Herbst R, Palombella VJ, Adams J. The proteasome inhibitor PS-341 in cancer therapy. Clin Cancer Res 1999;5:2638-45.
12. Andre P, Groettrup M, Klenerman P et al. An inhibitor of HIV-1 protease modulates proteasome activity, antigen presentation, and T cell responses. Proc Natl Acad Sci USA 1998;95:13120-4.
13. Elliott PJ, Pien CS, McCormack TA, Chapman ID, Adams J. Proteasome inhibition: a novel mechanism to combat asthma. J Allergy Clin Immunol 1999;104:294-300.
14. Goldberg AL, Rock K. Not just research tools - proteasome inhibitors offer therapeutic promise. Nat Med 2002;8:338-40.
15. Luo H, Wu Y, Qi S, Wan X, Chen H, Wu J. A proteasome inhibitor effectively prevents mouse heart allograft rejection. Transplantation 2001;72:196-202.
16. Hosseini H, Andre P, Lefevre N et al. Protection against experimental autoimmune encephalomyelitis by a proteasome modulator. J Neuroimmunol 2001;1888:244.
17. Zollner TM, Podda M, Pien C, Elliott PJ, Kaufmann R, Boehncke WH. Proteasome inhibition reduces superantigen-mediated T cell activation and the severity of psoriasis in a SCID-hu model. J Clin Invest 2002;109:671-9.
18. Rock KL, Goldberg AL. Degradation of cell proteins and the generation of MHC class I-presented peptides. Annu Rev Immunol 1999;17:739-79.
19. Meng L, Mohan R, Kwok BH, Elofsson M, Sin N, Crews CM. Epoxomicin, a potent and selective proteasome inhibitor, exhibits in vivo antiinflammatoty activity. Proc Natl Acad Sci USA 1999;96:10403-8.
20. Wang JI, Hongyu L, Chen H, Duguid W, Wu J. Role of proteasome in T cell activation and proliferation. J Immunol 1998;160:788-801.
21. Yang Y, Fang S, Jensen JP, Weissman AM, Ashwell JD. Ubiquitin protein ligase activity of IAPs and their degradation in proteasomes in response to apoptotic stimuli. Science 2000;288:874-7.
22. Kisselev AF, Goldberg AL. Proteasome inhibitors: from research tools to drug candidates. Chem Biol 2001;8:739-58.
23. Tsubuki S, Saito Y, Tomioka M, Ito H, Kawashima S. Differential inhibition of calpain and proteasome activities by peptidyl aldehydes of di-leucine and tri-leucine. J Biochem (Tokyo) 1996;119:572-6.
24. Judowski V, Pinilla C, Schroder K, Tucker L, Sarvetnick N, Wilson DB. Identification of MHC class II-restricted peptide ligands, including a glutamic acid decarboxylase 65 sequence, that stimulate diabetogenic T cells from transgenic BDC2.5 nonobese diabetic mice. J Immunol 2001;166:908-17.
25. Luhder F, Chambers C, Allison JP, Benoist C, Mathis D. Pinpointing when T cell costimulatory receptor CTLA-4 must be engaged to dampen diabetogenic T cells. Proc Natl Acad Sci USA 2000;97:12204-9.
26. Lee DH, Goldberg AL. Proteasome inhibitors: valuable new tools for cell biologists. Trends Cell Biol 1998;8:397-403.
27. Andre-Schmutz I, Hindelang C, Benoist C, Mathis D. Cellular and molecular changes accompanying the progression from insulitis to diabetes. Eur J Immunol 1999;29:245-55.
28. Katz JD, Wang B, Haskins K, Benoist C, Mathis D. Following a diabetogenic T cell from genesis through pathogenesis. Cell 1993;74:1089-100.
29. Gumunsdottir H, Wells AD, Turka LA. Dynamics and requirements of T cell clonal expansion in vivo at the single-cell level: effector function is linked to proliferative capacity. J Immunol 1999;162:5212-23.
30. Mehr R, Shahaf G, Sah A, Cancro M. Asynchronous differentiation models explain bone marrow labeling kinetics and predict reflux between the pre- and immature B cell pools. Int Immunol 2003;15:301-12.
31. Wang X, Omura L, Szeweda I, Yang Y, Berard J, Wu J. Rapamycin inhibits proteasome activator expression and proteasome activity. Eur J Immunol 1997;27:2781-6.
32. Sadoul R, Fernandez PA, Quiquerez AL, Martinou I, Maki M, Schroter M, Becherer JD, Irmler M, Tschopp J, Martinou JC. Involvement of the proteasome in the programmed cell death of NGF-deprived sympathetic neurons. EMBO J 1996;15:3845-52.
33. Kwon G, Corbett JA, Hauser S, Hill JR, Turk J, McDaniel ML. Evidence for involvement of the proteasome complex (26S) and NFkappaB in IL-1 beta-induced nitric oxide and prostaglandin production by rat islets and RINm5F cells. Diabetes 1998;47:583-91.
34. Gonzalez A, Katz JD, Mattei MG, Kikutani H, Benoist C, Mathis D. Genetic control of diabetes progression. Immunity 1997;7:873-83.